Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 420-425

  Tsai, Tzu Hsiu ^a   Yang, Ching Yao ^a   Ho, Chao Chi ^a   Liao, Wei Yu ^a   Jan, I Shiow ^a   Chen, Kuan Yu ^a   Wang, Jann Yuan ^a   Ruan, Sheng Yuan ^a   Yu, Chong Jen ^a   Yang, James Chih Hsin ^a,b   Yang, Pan Chyr ^a   Shih, Jin Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

EGFR mutation; EML4 ALK fusion; Endobronchial ultrasound; Flexible bronchoscopy; K ras mutation; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; RNA;

ARTICLE; BRONCHOSCOPE; BRONCHOSCOPY; CYTOLOGY; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOBRONCHIAL ULTRASOUND ASSISTED BRONCHOSCOPY; GENE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SARCOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSTICS; MULTICENTER STUDY; MUTATION; PERIPHERAL LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; TRANSBRONCHIAL BIOPSY; TUMOR CELL; WASTE BRUSHING SAMPLE; WILD TYPE;

EGFR MUTATION; EML4-ALK FUSION; ENDOBRONCHIAL ULTRASOUND; FLEXIBLE BRONCHOSCOPY; K-RAS MUTATION; TARGETED THERAPY;

ADENOCARCINOMA; BRONCHI; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL CELLS; FEASIBILITY STUDIES; GENES, ERBB-1; GENES, RAS; GENOTYPE; HUMANS; LUNG NEOPLASMS; MEDICAL WASTE; MICROVILLI; MUTATION; ONCOGENE PROTEINS, FUSION; PATHOLOGY, MOLECULAR; REPRODUCIBILITY OF RESULTS; RNA; SPECIMEN HANDLING;

EID: 84887615354     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.005     Document Type: Article

References (30)

1. Mok T.S. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
4. Aisner D.L., Marshall C.B. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol 2012, 138:332-346.
5. Rivera M.P., Mehta A.C. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl.):131S-148S.
6. Paone G., Nicastri E., Lucantoni G., Dello Iacono R., Battistoni P., D'Angeli A.L., et al. Endobronchial ultrasound-driven biopsy in the diagnosis of peripheral lung lesions. Chest 2005, 128:3551-3557.
7. Steinfort D.P., Khor Y.H., Manser R.L., Irving L.B. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. Eur Respir J 2011, 37:902-910.
8. Hergott C.A., Tremblay A. Role of bronchoscopy in the evaluation of solitary pulmonary nodules. Clin Chest Med 2010, 31:49-63.
9. Coghlin C.L., Smith L.J., Bakar S., Stewart K.N., Devereux G.S., Nicolson M.C., et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 2010, 5:448-452.
10. Reck M., Hermes A., Tan E.H., Felip E., Klughammer B., Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer 2011, 74:1-6.
11. Tsai T.H., Su K.Y., Wu S.G., Chang Y.L., Luo S.C., Jan I.S., et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J 2012, 39:677-684.
12. Wu S.G., Gow C.H., Yu C.J., Chang Y.L., Yang C.H., Hsu Y.C., et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008, 32:924-930.
13. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
14. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
15. Huang C.T., Tsai Y.J., Liao W.Y., Wu P.C., Ho C.C., Yu C.J., et al. Endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: how many specimens are necessary?. Respiration 2012, 84:128-134.
16. Wu S.G., Kuo Y.W., Chang Y.L., Shih J.Y., Chen Y.H., Tsai M.F., et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type egfr. J Thorac Oncol 2012, 7:98-104.
17. Sasaki T., Rodig S.J., Chirieac L.R., Jänne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
18. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009, 117:67-72.
19. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007, 13:4954-4955.
20. Malapelle U., Bellevicine C., Zeppa P., Palombini L., Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol 2011, 39:703-710.
21. Savic S., Tapia C., Grilli B., Rufle A., Bihl M.P., de Vito Barascud A., et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008, 98:154-160.
22. Chowdhuri S.R., Xi L., Pham T.H., Hanson J., Rodriguez-Canales J., Berman A., et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012, 25:548-555.
23. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:201-205.
24. Lam W.K. Lung cancer in Asian women-the environment and genes. Respirology 2005, 10:408-417.
25. Wu C.C., Hsu H.Y., Liu H.P., Chang J.W., Chen Y.T., Hsieh W.Y., et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008, 113:3199-3208.
26. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007, 21:3214-3231.
27. Kanaji N., Bandoh S., Ishii T., Kushida Y., Haba R., Kohno K., et al. Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. Mol Diagn Ther 2011, 15:353-359.
28. Kanaji N., Bandoh S., Ishii T., Tadokoro A., Watanabe N., Takahama T., et al. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. Lung Cancer 2012, 77:293-298.
29. Soda M., Isobe K., Inoue A., Maemondo M., Oizumi S., Fujita Y., et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 2012, 18:5682-5689.
30. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.